as template, DHPLC allows the analysis of amplicons including more than one exon at time. For this reason, DHPLC assay is a good approach suitable to identify genetic aberrations occurring outside the specific mutational hot spot. Only the samples showing an abnormal chromatogram are subsequently sequenced. As an alternative, immunohistochemistry that detects, through cytoplasmic dislocation on NPM, 'all types' of NPM1 mutations, 3,4 could serve as first step for directing further molecular studies, i.e. restricting analysis for NPM1 exons other than exon-12 to AML cases that may turn out to be NPM cytoplasmicpositive in the absence of exon-12 NPM1 mutations. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia Leukemia (2007) A gain-of-function mutation at codon 617(V617F) of the Janus kinase 2 (JAK2) gene has been reported in chronic myeloproliferative diseases. The JAK2V617F results in a valine to phenylalanine substitution causing constitutive activation of the JAK-STAT pathway. This in turn leads to proliferation of the hematopoietic cells. 1 Jelinek et al. 2 recently published results of a study of the first large series of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) patients with the JAK2V617F mutation. The mutation was not found in 99 CML patients, including 55 imatinib-resistant patients.
Recently, we encountered a JAK2V617F-and Ph-positive CML patient being treated with imatinib that evolved to erythrocytosis needing phlebotomy during cytogenetic complete remission (CCR).
The patient was a 43-year-old man diagnosed as chronic phase CML with a 49% hematocrit (Ht). Cytogenetic analysis revealed a karyotype of 46, XY, t(9;22)(q34;q11) in all the metaphases(20/20). The type of BCR-ABL was b2a2. He was treated with interferon a-2b (IFN-a) followed by hematological remission. One year later he showed leukocytosis again and was diagnosed as 'transformation to accelerated phase' with no additional chromosomal aberration. Because there was no HLA-matched donor, he could not receive hematopoietic stem cell transplantation. Thus, he was treated with IFN-a and hydroxyurea to control CML for another 5 years. After imatinib was approved in Japan, IFN-a and hydroxyurea were stopped and imatinib therapy was started. One month following commencement of imatinib therapy, hematological remission was achieved and CCR was obtained at 33 months. Two months before imatinib administration, intriguingly, erythrocytosis developed. Although imatinib was effective for CML, the red blood cell count gradually increased. As the Ht value exceeded 50%, phlebotomy has been performed since then intermittently.
To investigate the mechanism of erythrocytosis, search for the mutation and quantify the level of the JAK2V617F, real-time quantitative polymerase chain reaction (RQ-PCR) was performed using a Gene Amp 5700 sequence detection system (Applied Biosystems, CA, USA). For JAK2 gene mutational and quantitative analysis, genomic DNA of the subject's bone marrow mononuclear cells was isolated using the QIAamp DNA Mini Kit (QIAGEN, Stanford, CA, USA). Allele-specific (AS-) PCR was also performed. 3 To determine the status of CML, we had performed fluorescence in situ hybridization (FISH) of BCR-ABL gene. AS-PCR detected the JAK2V617F beginning at the onset of CML and throughout his clinical course. (Figure 1a ) As there were JAK2V617F from the onset of CML, we performed an RQ-PCR-based allelic discrimination assay to quantify the level of JAK2V617F. 4 Sequential evaluation of JAK2V617F-mutant alleles in the bone marrow cells revealed that the percentage of cells harboring the JAK2V617F mutation did not change throughout the course (Figure 1b) .
As in the clinical course, erythrocytosis appeared and expanded in contrast to CML clone, which were decreased in number by administering imatinib. These findings speculate that the clone harboring JAK2V617F existed from the CML onset, together with the CML clone, which were transiently suppressed by IFN-a. However, the JAK2V617F clone has steadily survived under IFN-a and erythrocytosis gradually developed in inverse proportion to the suppression of the CML clone by imatinib. This is the first report of a CML patient with the JAK2V617F mutation. We report on reciprocal FIP1L1/RARA fusion transcripts resulting from a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia (JMML). JMML is a pediatric myeloproliferative disease (MPD), characterized by proliferation of granulocytic and monocytic lineages with in vitro hypersensitivity to granulocyte/macrophage colony stimulating factors (GM-CSF). Mutations in N/K-RAS (20-30%), PTPN11 (35%) and NF1 (10%) have been identified, indicating deregulation of the RAS/MAPK pathway in JMML. 17q12 RARA was demonstrated to be involved in t(15;17)(q22;q21), resulting in a PML/RARA fusion transcript. PML/RARA t(15;17) is the hallmark of acute promyelocytic leukemia (APL), characterized by a differentiation arrest of abnormal promyelocytes. 1 Variant rearrangements involving 17q21 RARA in APL and APL-like (APL-L) disease are PLZF/RARA t(11;17)(q23;q21), NPM1/RARA t(5;17)(q35;q21), NUMA/RARA t(11;17)(q13;q21), STAT5b/RARA der(17) and t(3;17)(p25;q21).
1,2 All known RARA fusion protein partners have the ability to self-associate, which is critical for oncogenesis. 3 In chronic eosinophilic leukemia (CEL) an FIP1L1/ PDGFRA fusion gene has been identified owing to a chromosome 4q12 interstitial deletion. 4 FIP1L1 is an integral subunit of cleavage and polyadenylation specificity factor (CPSF) and interacts with poly(A)polymerase (PAP) to stimulate polyadenylation.
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In March 1996, a 20-month-old boy was admitted because of progressive fatigue, pallor, fever and tachypnea. A pericardial 
